ACE inhibitor pathway (WP554)

The core of this pathway was elucidated over a century ago and involves the conversion of angiotensinogen to angiotensin I (Ang I) by renin, its subsequent conversion to angiotensin II (Ang II) by angiotensin converting enzyme. Ang II activates the angiotensin II receptor type 1 to induce aldosterone synthesis, increasing water and salt resorption and potassium excretion in the kidney and increasing blood pressure. Source: PharmGKB (https://www.pharmgkb.org/pathway/PA2023) Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP554 CPTAC Assay Portal]
last edited

Authors

C.F.Thorn, MaintBot, Jinwook, Khanspers, AlexanderPico, Thomas, MartijnVanIersel, Egonw, Christine Chichester, Nuno, DeSl, Mkutmon, and Eweitz

Cited In

Organism

Homo sapiens

Communities

COVID-19 Renal Genomics Pathways

Annotations

Cell Type Ontology: mesangial cell

Pathway Ontology: angiotensin signaling pathway signaling pathway ACE inhibitor drug pathway

Disease Ontology: hypertension

Participants

Label Type Compact Identifier
Ang 1-5 Metabolite kegg.compound:C15852
Aldosterone Metabolite hmdb:HMDB0000037
Bradykinin Metabolite hmdb:HMDB0004246
Angiotensin II Metabolite hmdb:HMDB0001035
Ca++ Metabolite hmdb:HMDB0000464
Angiotensin I Metabolite pubchem.compound:3081372
ACE Inhibitor Metabolite chebi:35457
Deoxycorticosterone Metabolite hmdb:HMDB0000016
Ang 1-7 Metabolite chemspider:110354
Prostacyclin Metabolite pubchem.compound:114805
Ang 1-9 Metabolite kegg.compound:C15851
NOS3 GeneProduct ncbigene:4846
AGTR2 GeneProduct ncbigene:186
BDKRB1 GeneProduct ncbigene:623
TFs GeneProduct None
AGTR1 GeneProduct ncbigene:185
TGFB1 GeneProduct ncbigene:7040
CTSG GeneProduct ncbigene:1511
KNG1 GeneProduct ncbigene:3827
ACE GeneProduct ncbigene:1636
CMA1 GeneProduct ncbigene:1215
REN GeneProduct ncbigene:5972
CYP11B2 GeneProduct ncbigene:1585
MAS1 GeneProduct ncbigene:4142
ACE2 GeneProduct ncbigene:59272
AGT GeneProduct ncbigene:183
NR3C2 GeneProduct ncbigene:4306
ATP6AP2 GeneProduct ncbigene:10159
ACE GeneProduct ncbigene:1636
BDKRB2 GeneProduct ncbigene:624
TFs GeneProduct None
ACE GeneProduct ncbigene:1636
ACE2 GeneProduct ncbigene:59272

References

  1. Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase expression. Mol Cell Endocrinol. 2004 Mar 31;217(1–2):67–74. PubMed Europe PMC Scholia
  2. Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics. 2004;4(3):151–60. PubMed Europe PMC Scholia
  3. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006 Jan;69(1):105–13. PubMed Europe PMC Scholia
  4. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus ADME, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007 May;212(1):1–11. PubMed Europe PMC Scholia
  5. Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther. 2007 Sep;29(9):1803–24. PubMed Europe PMC Scholia
  6. Batenburg WW, Jan Danser AH. The (pro)renin receptor: a new addition to the renin-angiotensin system? Eur J Pharmacol. 2008 May 13;585(2–3):320–4. PubMed Europe PMC Scholia
  7. Ferreira AJ, Raizada MK. Are we poised to target ACE2 for the next generation of antihypertensives? J Mol Med (Berl). 2008 Jun;86(6):685–90. PubMed Europe PMC Scholia
  8. Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and endothelial function. Curr Opin Investig Drugs. 2008 Sep;9(9):963–9. PubMed Europe PMC Scholia